Paglalarawan

An orphan drug is a medicine for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition that is rare or where the medicine is unlikely to generate sufficient profit to justify research and development costs. They are orphans because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions. The global orphan drugs market is set to grow by US$ 69 bilyon sa panahon ng 2021-2027, lumalaki sa isang compound taunang rate ng paglago (CAGR) ng mga 5.5% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix. Availability of exclusivity for orphan drugs, rising prevalence of rare diseases, favorable government policies are expected to boost the market growth in the coming years.

Ang ulat ay nagbibigay ng napapanahong data ng laki ng merkado para sa panahon 2017-2020 at forecast na 2027 covering key market aspects like sales value for orphan drugs. The global orphan drugs market is segmented on the basis of drug type, top selling drug, disease type, at rehiyon. By drug type, it is categorized into biological drugs, and non-biological drugs. The biological drugs segment held the largest market share in 2020. By top selling drug, the orphan drugs market is divided into Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, at iba pa. The Revlimid segment accounted for the largest market share in 2020. Based on disease type, the orphan drugs market is divided into oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, at iba pa.

The report has profiled some of the key players of the market such as AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Celgene Corporation, CSL Behring GmbH, Eisai Co. Ltd., F. Hoffmann-La Roche AG, Incyte Corporation, Jiangsu Hengrui Medicine Co. Ltd., Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi S.A., Syros Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Vertex Pharmaceuticals Inc..

Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the orphan drugs market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

Saklaw ng Ulat

Drug type: biological drugs, and non-biological drugs
Top selling drug: Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, at iba pa
Disease type: oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, at iba pa
Rehiyon: Hilagang Amerika, Asya Pasipiko, Europa, and Rest of the World (ROW)
Mga Taon na Itinuturing: Ang ulat na ito ay sumasaklaw sa panahon 2017 sa 2027

Mga Pangunahing Benepisyo para sa mga Stakeholder

Get a comprehensive picture of the global orphan drugs market
Tukuyin ang mga estratehiya sa rehiyon at mga estratehikong prayoridad batay sa lokal na data at pagsusuri
Pinpoint ang mga sektor ng paglago at mga trend para sa pamumuhunan
Understand what the future of the global orphan drugs market looks like
Kilalanin ang mapagkumpitensya na landscape at window ng pagkakataon

Talaan ng mga Nilalaman

1. Kahulugan ng Market
2. Metodolohiya ng Pananaliksik
3. Market Data & Outlook
3.1 Halaga ng Market
3.2 Pagtataya ng Halaga sa Market
4. Orphan Drugs Market by Drug Type
4.1 Biological Drugs
4.2 Non-Biological Drugs
5. Orphan Drugs Market by Top Selling Drug
5.1 Revlimid
5.2 Tafinlar
5.3 Hemlibra
5.4 Darzalex
5.5 Kyprolis
5.6 Myozyme
5.7 Vyndaqel
5.8 Soliris
5.9 Ninlaro
5.10 Imbruvica
5.11 Ang iba naman
6. Orphan Drugs Market by Disease Type
6.1 Oncology
6.2 Blood Disorders
6.3 Central Nervous System
6.4 Respiratory System
6.5 Immunomodulators
6.6 Cardiovascular Therapies
6.7 Ang iba naman
7. Orphan Drugs Market by Region
7.1 Hilagang Amerika
7.2 Asya Pasipiko
7.3 Europa
7.4 Rest Of The World (Row)
8. Mga Profile ng Kumpanya
8.1 AbbVie Inc.
8.2 Alexion Pharmaceuticals Inc.
8.3 Amgen Inc.
8.4 AstraZeneca plc
8.5 Biogen Inc.
8.6 BioMarin Pharmaceutical Inc.
8.7 Bristol-Myers Squibb Company
8.8 Celgene Corporation
8.9 CSL Behring GmbH
8.10 Eisai Co., Ltd.
8.11 F. Hoffmann-La Roche AG
8.12 Incyte Corporation
8.13 Jiangsu Hengrui Medicine Co., Ltd.
8.14 Johnson & Johnson
8.15 Novartis AG
8.16 Pfizer Inc.
8.17 Sanofi S.A.
8.18 Syros Pharmaceuticals, Inc.
8.19 Takeda Pharmaceutical Co. Ltd.
8.20 Vertex Pharmaceuticals, Inc.
9. Apendiks
9.1 Tungkol sa StrategyHelix
9.2 Pagtanggi